Z

Zomedica Corp
AMEX:ZOM

Watchlist Manager
Zomedica Corp
AMEX:ZOM
Watchlist
Price: 0.1282 USD -1.38% Market Closed
Market Cap: 125.6m USD
Have any thoughts about
Zomedica Corp?
Write Note

Net Margin
Zomedica Corp

-232.7%
Current
-2 986%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-232.7%
=
Net Income
-62.2m
/
Revenue
26.7m

Net Margin Across Competitors

Country US
Market Cap 125.6m USD
Net Margin
-233%
Country US
Market Cap 205.2B USD
Net Margin
14%
Country US
Market Cap 193.1B USD
Net Margin
29%
Country US
Market Cap 148.6B USD
Net Margin
16%
Country US
Market Cap 132.9B USD
Net Margin
11%
Country IE
Market Cap 109.9B USD
Net Margin
13%
Country US
Market Cap 64.8B USD
Net Margin
9%
Country DE
Market Cap 56.6B EUR
Net Margin
8%
Country CN
Market Cap 326.2B CNY
Net Margin
33%
Country US
Market Cap 42.2B USD
Net Margin
74%
Country US
Market Cap 37.7B USD
Net Margin
9%
No Stocks Found

Zomedica Corp
Glance View

Market Cap
125.6m USD
Industry
Health Care

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 85 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).

ZOM Intrinsic Value
0.1271 USD
Overvaluation 1%
Intrinsic Value
Price
Z

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-232.7%
=
Net Income
-62.2m
/
Revenue
26.7m
What is the Net Margin of Zomedica Corp?

Based on Zomedica Corp's most recent financial statements, the company has Net Margin of -232.7%.